1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 71335-1149
  5. Product Images: Rizatriptan Benzoate

Product Images Rizatriptan Benzoate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Rizatriptan Benzoate NDC 71335-1149 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label Image - lbl713351149

Label Image - lbl713351149

This is a medication description for Rizatriptan tablet, which is pink and round in shape, containing Benzoate 5mg. The tablet should be stored at room temperature, and it is available in a blister pack of Maxalt Sm%. The medication is manufactured by Rising Health LLC and comes in a package of 30 tablets. The NDC code for this tablet is 7133511491 06613301523487.*

Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1

Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1

The given text shows a graph representing the probability of achieving an initial headache response after treatment with placebo or two doses of Rizatriptan Benzoate (5mg, 10mg) within the first two hours. The data is based on pooled results from four outpatient trials (Studies 1, 2, 3, and 4) and displays the Kaplan-Meier plot. Patients who did not achieve headache response within two hours or took additional treatment were censored at 2 hours.*

Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2

Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2

This figure shows the estimated probability of patients taking a second dose of either Rizatriptan Benzoate tablets or other medication for migraines over 24 hours following the initial dose of study treatment. The table includes the percentage of patients taking either Rizatriptan Benzoate 5 mg or 10 mg at different times post-dose. This data is based on 4 placebo-controlled outpatient clinical trials and includes patients who had a headache response at 2 hours and those who had no response to the initial dose. Patients not using additional treatments were censored at 24 hours. Remedication was not allowed within 2 hours post-dose.*

Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig3

Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig3

Chemical Structure - rizatriptan str

Chemical Structure - rizatriptan str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.